PROGNOSTIC VALUE OF FDG UPTAKE OF PRIMARY TUMOR AND METASTATIC LESIONS IN ADVANCED NON-SMALL CELL LUNG CANCER by Nguyen, Xuan Canh
 1 
 
 
UNIVERSITÀ DEGLI STUDI DI NAPOLI FEDERICO II 
 
 
 
THESIS 
 
PROGNOSTIC VALUE OF FDG UPTAKE OF 
PRIMARY TUMOR AND METASTATIC LESIONS 
IN ADVANCED NON-SMALL CELL LUNG CANCER 
 
Nguyen Xuan Canh, MD, MSc 
 
 
Tutors: 
 
 Prof. Marco Salvatore 
 Prof. Simone Maurea 
 
 
 
 
March, 2013 
 
 
 2 
 
Contents Page 
1. ABBREVITATIONS 4 
2. ABSTRACT 6 
3. INTRODUCTION 7 
4. BACKGROUND 10 
 4.1. Introduction of PET and PET/CT  10 
 4.2. FDG-PET in diagnosis of a solitary pulmonary nodule 12 
 4.3. FDG-PET in staging lung cancer 13 
 4.4. Prognostic value of FDG-PET in non-small cell lung  
    cancer (NSCLC) 
15 
 4.4.1. Prognosis value of FDG uptake of primary tumor  
     in stage I and II NSCLC 
16 
 4.4.2. Prognostic value of FDG uptake of primary tumor  
     in stage III-IV NSCLC 
19 
 4.4.3. Prognostic value of FDG uptake of primary tumor    
     in all stage of NSCLC 
22 
 4.4.4. Beyond of FDG uptake of primary tumor 24 
5. AIM OF STUDY 28 
6. MATERIALS AND METHODS 29 
 6.1. Patient population 29 
 6.2. FDG-PET/CT Imaging 29 
 6.3. Measurement of FDG uptake on PET/CT 31 
 6.4. Data analysis 34 
 
 
 3 
7. RESULTS 35 
 7.1. Patient characteristics 35 
 7.2. Univariate analysis of overall survival 38 
 7.3. Multivariate analysis with respect to overall survival 43 
 7.4. Survival analysis in patients with stage IV NSCLC 47 
8. DISCUSSION  48 
9. CONCLUSION 53 
10. REFERENCE  54 
11. APPENDIX 59 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 4 
1. ABBREVITATIONS 
 
18
F-FDG 2-deoxy-2-[
18
F]-fluoro-D-glucose 
ASR Age Standardized Rate 
FDG 2-deoxy-2-[
18
F]-fluoro-D-glucose  
FDG-PET Positron emission tomography with 2-deoxy-2-[
18
F]-
fluoro-D-glucose 
FDG-PET/CT 2-deoxy-2-[
18
F]-fluoro-D-glucose Positron emission 
tomography / computed tomography  
NSCLC Non-small cell lung cancer 
maxSUV Maximum standardized uptake value 
maxSUVpt maxSUV of primary tumor 
maxSUVwb maxSUV of whole body tumors 
meanSUV Mean standardized uptake value 
MTV Metabolic tumor volume 
Nn Number of nodal metastases 
non-sqc Non-squamous cell carcinoma 
PET Positron emission tomography 
PET/CT Positron emission tomography / computed tomography 
SCLC Small cell lung cancer 
sumaxSUV Sum of maxSUVs of primary tumor, lymph nodes, and 
metastatic lesions per each organ in whole body. 
SUV Standardized uptake value  
sqc Squamous cell carcinoma 
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TLG Total lesion glycolysis  
TNM Tumor - node - metastasis 
TTn Total number of tumors 
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2. ABSTRACT 
Purpose: To assess the prognostic value of metabolic tumor burden as sumaxSUV measured 
by sum of the maxSUVs of primary tumor, metastatic lymph nodes and metastatic lesions per 
each organ on FDG-PET/CT in patients with advanced NSCLC. 
Materials and methods: Eighty three patients with advanced NSCLC were enrolled. 
Seventeen patients had stage IIIA, 21 had stage IIIB and 45 had stage IV. SumaxSUV, 
maxSUV of primary tumor (maxSUVpt), maxSUV of whole body tumors (maxSUVwb), age, 
gender, tumor-cell type, T stage, N stage, overall stage, primary tumor size, specific treatment 
were analyzed for correlation with overall survival. Median follow-up duration was 13 
months. 
Results: Fifty (60.2%) of the 83 patients were dead during a median follow-up time of 11 
months and 33 patients (39.8%) were alive with a median follow-up time of 15 months. 
Univariate analysis revealed that overall survival was significantly correlated with 
sumaxSUV (≥35 vs. <35, p = 0.004), T stage (T4 vs. T1-T3, p = 0.025), overall stage (IV vs. 
III, p = 0.002), gender (male vs. female, p = 0.029) and specific treatment (no vs. yes, p = 
0.011). Multivariate analysis identified sumaxSUV, T stage, gender and specific treatment as 
independent prognostic indicators in advanced NSCLC. Patients with a sumaxSUV of  35 
were 1.921 times more likely to die from NSCLC than those with a sumaxSUV of ≤35 (p = 
0.047). The median survival time was 14 months for patients with sumaxSUV 35 compared 
to 20 months for those with sumaxSUV <35. In patients with metastatic NSCLC, sumaxSUV 
with cut-off of 35 was much more significant for survival prognosis (p = 0.021). 
Conclusion: SumaxSUV is a new prognostic measure, independent of tumor stage, gender 
and specific treatment in advanced NSCLC. SumaxSUV may be better than maxSUVpt and 
maxSUVwb in prediction of survival in advanced NSCLC. A large prospective cohort study is 
necessary to validate these results. 
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3. INTRODUCTION 
Lung cancer is one of the leading causes of cancer deaths throughout the world. 
The disease accounted for 1.3 million deaths in 2004 following the report of 
WHO [1].  
In Vietnam, lung cancer was the most common in males and the six most 
common in females after breast cancer, cervical cancer, stomach cancer, liver 
cancer and colorectal cancer. The Age Standardized Rate (ASR) of lung cancer 
was 24.6 in males and 6.8 in females in Hochiminh city and 38.8 in males and 
5.6 in females in Hanoi city [2].  
At present, prognosis in non-small cell lung cancer (NSCLC) primarily depends 
on tumor-node-metastasis (TNM) stage [3, 4], and the oncologists commonly 
use TNM staging system for deciding the best treatment methods for the 
patients.  
However, the staging system is not entirely satisfactory in terms of explaining 
relative risk of recurrence, and death. It is likely due to the heterogeneous nature 
of disease stage. Besides of early stage disease at diagnosis, certain other 
prognostic factors are predictive of survival in patients with NSCLC such as 
performance status, weight loss, and gender [5]. 
NSCLC features the characteristics of derangements of glucose metabolism. 
Increased glucose consumption, and glycolytic activity have been reported in 
NSCLC [6], and the altered glucose metabolism can be assessed in vivo by 
positron emission tomography (PET) using 2-deoxy-2-[
18
F]-fluoro-D-glucose 
(FDG) [7]. The level of FDG uptake of the tumor can be quantiﬁed by the 
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standardized uptake value (SUV) on PET, and the maxSUV is representative 
parameter for the maximal glucose metabolism of the tumor.  
FDG uptake of primary tumor has been identified as an independent prognostic 
indicator for survival in early stage NSCLC at diagnosis [8-14], however, its 
prognostic value has been found disappointing in advanced NSCLC [15-18]. 
Recent studies reported that initial prognosis in NSCLC was related with tumor 
burden measurement. Whole body metabolic tumor volume (MTV), total lesion 
glycolysis (TLG) and total number of tumors (TTn) have been found to be 
correlated with survival in patients with stage I-IV [19-23], and also in separate 
stage IV NSCLC [24].  
It seems that FDG uptake of primary tumor on FDG-PET may be an 
independent prognostic factor for early stage NSCLC, which may be treated by 
surgical resection and whole body tumor burden may be responsible for 
prognosis in advanced NSCLC.  
On the other hand, level of FDG uptake in primary tumor significantly 
correlated with the incidence of regional lymph node metastasis [25, 26], and 
distant metastases in NSCLC [15, 27]. The aggression of primary tumor and 
metastatic lesions, which can contribute to the actual causes of death in 
advanced NSCLC may be reflected by evaluation of glucose metabolic activity 
by FDG uptake on PET or PET/CT.  
It is unknown whether there is correlation between survival, and metabolic 
tumor burden measured by sum of highest glucose metabolism levels of primary 
tumor, metastatic lymph nodes and metastatic lesions per each organ, 
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represented by so-called sumaxSUV, which is calculated by sum of maxSUV of 
primary tumor, maxSUV of metastatic lymph nodes, and maxSUV of metastatic 
lesions per each organ in patients with advanced NSCLC. 
This prospective study was to test our hypothesis on prognostic value of 
sumaxSUV measurement, and other conventional factors on overall survival in 
patients with advanced NSCLC. 
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4. BACKGROUND   
4.1. Introduction of PET and PET/CT 
Positron emission tomography (PET) is a powerful, non-invasive nuclear 
medical imaging that provides metabolic information within the human body. 
PET can detect and follow-up variety of diseases with changes in metabolism 
which often precedes changes in structure or anatomy. PET has been 
extensively using in fields of oncology, neurology and cardiology.  
From year of 2000, PET/CT with integration of PET and computed tomography 
(CT) scanners in one combined scanning system that can provide metabolic and 
anatomic information in the human body in a single scan. The CT in PET/CT is 
used for attenuation correction, better localization of lesions in the body and 
anatomic diagnosis with using contrast media. 
2-deoxy-2-[
18
F]-fluoro-D-glucose (
18
F-FDG or FDG), a positron emitting 
radiopharmaceutical is commonly used in PET imaging (FDG-PET). Fluorine 
18
F in FDG is radioactive isotope, which decays by positron (β+) emission and 
has a half-life of 109.7 minutes.  
FDG is administered by intravenous injection. FDG, a glucose analog, 
concentrates in cells that rely upon glucose as an energy source, or in cells 
whose dependence on glucose increases under pathophysiological conditions. 
FDG is transported through the cell membrane by facilitative glucose 
transporter proteins and is phosphorylated within the cell to FDG-6-phosphate 
by the enzyme hexokinase. Once phosphorylated, it cannot exit until it is 
dephosphorylated by glucose-6-phosphatase. Therefore, within a given tissue or 
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pathophysiological process, the retention and clearance of FDG reflect a 
balance involving glucose transporter, hexokinase and glucose-6-phosphatase 
activities [28].  
FDG-PET reflects glucose metabolism and has been used for diagnosis and 
follow-up of cancers. The advantage of PET technique is the ability to quantity 
the tracer uptake. Standardized uptake value (SUV), a semi-quantitative 
parameter is measured on PET. SUV is calculated by (activity concentration in 
tissue) / (injected activity / body size). The body size can be measured for body 
weight, lean body mass or body surface area. Body weight is more frequently 
used in SUV calculation. 
To measure SUV, a region of interest (ROI) or a volume of interest (VOI) is 
drawn in the target tissue using interactive workstation. The software will 
generate the value of SUV by the programming formula calculation. Mean SUV 
and maximum SUV (maxSUV) can be used in clinical application. MaxSUV is 
the most frequently used and represents the highest FDG uptake in PET or 
PET/CT. MaxSUV value reflects the highest level of glucose metabolic activity 
in target tissue. 
In the field of oncology, FDG-PET and PET/CT are put into clinical application 
for diagnosis, follow-up and prognosis of cancerous diseases.   
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4.2. FDG-PET in diagnosis of a solitary pulmonary nodule 
The initial application of FDG-PET in lung cancer is to differentiate benign 
from malignant solitary pulmonary nodule (SPN). SPN is one of the most 
common radiological abnormalities that require further clinical work-up to 
confirm a benign or malignant lesion or periodic follow-up.  
Assessment of morphologic characteristics, including size, contour, margins and 
internal characteristics was not completely reliable with conventional imaging 
to differentiate benign or malignant SPNs [29].  
Diagnosis of malignant SPN is improved by using contrast-enhance CT and 
PET. Malignant nodules were significantly enhanced on contrast CT more than 
granulomas and benign neoplasms. With 20 HU as the threshold for a positive 
test result, the sensitivity was 98%, specificity was 73%, and accuracy was 
85%. Enhancement appeared to be an indicator of malignancy and vascularity 
[30].  
FDG-PET is a noninvasive method to assess indeterminate SPNs and helps 
reduce the need for invasive biopsy. In general, the malignant lesions 
demonstrate glucose hypermetabolism and high level of FDG uptake in FDG-
PET. In a meta-analysis of study on accuracy of PET for diagnosis of pulmonary 
nodules and mass lesions, Gould, M.K., et al. found that FDG-PET was very 
sensitive (96.8%) though not very specific (77.8) in accuracy to differentiate 
malignant and benign lesions [31].  
The majority of false negative cases on FDG-PET was due to subcentimeter 
nodules [32-34], and certain histological types with low metabolic activity (such 
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as bronchioalveolar carcinoma and typical carcinoid) [34]. Common causes of 
false positive cases were granulomatous and infectious processes. FDG-PET has 
a high false positive rate in areas with a high incidence of tuberculosis and 
combined PET and CT (PET/CT) can improve the diagnostic accuracy in the 
differentiation of an SPN [35]. In a region with a high prevalence of pulmonary 
fungal infection, FDG-PET was sensitive but lower specific in detecting 
malignant SPNs [36]. 
 
4.3. FDG-PET in staging lung cancer 
FDG-PET has been found to be superior to conventional imaging in staging 
lung cancer. FDG-PET has the advantage of being able to detect distant 
metastases on a single whole body survey and is a reliable method for 
preoperative staging of patients with lung cancer and would help to optimize 
management.  
FDG-PET is more accurate than computed tomography in detecting mediastinal 
lymph node metastases. PET gave a sensitivity of 83% and speciﬁcity of 92% 
and CT gave sensitivity and speciﬁcity of 59 and 78%, respectively [37]. FDG-
PET correctly changed the N stage in 21-35% cases [38, 39]. In case of a 
negative FDG-PET for mediastinal lymph nodes, mediastinoscopy can be 
omitted and the patient may proceed directly to surgery. Differentiation between 
N2 and N3 lymph node metastasis is important to classify patients into stage 
IIIA or IIIB, which will be decided to do an operation or move to induction 
treatment. PET was superior to CT for correct identification between N2 and N3 
lymph node disease in lung cancer [40, 41]. 
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NSCLC commonly metastasizes to lymph nodes, bones, brain, liver and other 
regions of the body. PET and PET/CT was superior to conventional imaging in 
detection of distal metastasis. PET/CT revealed metastases in 20% of the 
patients without metastases found by conventional imaging and modified the 
stage of the disease in 28% of the cases [42]. 
For diagnosis of adrenal metastasis, FDG-PET was an accurate, noninvasive 
way and better than conventional imaging in differentiate benign from 
metastatic adrenal lesion. The sensitivity of FDG-PET for detecting adrenal 
metastatic disease was 97-100%, and the specificity was 80-94% in patients 
with lung cancer [43, 44].  
However, FDG-PET was found poor efficacy in detecting cerebral metastases, 
partially due to high background caused by physiologic cerebral FDG uptake. 
FDG uptake in metastatic brain lesions was variable. One third of brain 
metastasis from lung cancer showed glucose hypometabolism. NSCLC was 
more frequently associated with hypermetabolic metastatic brain lesions than 
small cell lung cancer (SCLC). The PET findings of brain lesions were affected 
not only by the size of lesion but also by its biological characteristics [45]. The 
sensitivity of FDG-PET/CT in revealing cerebral metastases in patients with 
lung adenocarcinoma has been reported at 24% in compared with 88% by brain 
MRI. Thus, adding dedicated brain MRI to PET/CT was necessary for 
enhancing detection of brain metastasis [46].  
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4.4. Prognostic value of FDG-PET in NSCLC 
Until now, TNM stage is the most important determinant of survival and a vital 
guide for treatment choices in NSCLC. The other prognostic factors include 
performance status, weight loss, and gender [5]. 
Recent advance in molecular biology and immunohistochemistry helps to 
understand about biomarkers and its influence on survival of patients with 
NSCLC. NSCLC presents derangements of glucose metabolism and cell 
proliferative activity. Glucose transporter type I (Glut-1) is a chief glucose 
transporter responsible for glucose uptake into the viable cell of NSCLC [47]. 
Overexpression of Glut-1 has been associated with poor prognosis of NSCLC 
[48, 49]. In addition, Ki-67 antigen is a molecular marker of tumor proliferation, 
and its over-expression has been linked to a poorer prognosis in NSCLC [50, 
51].  
FDG uptake of primary tumor may reflect activities of glucose metabolism and 
cell proliferation in NSCLC. Signiﬁcant correlations have been found between 
FDG uptake on PET and the biomarkers of glucose transport by Glut-1 
expression [52-55], and proliferative activity by Ki-67 expression in NSCLC 
[54-57]. In addition, FDG uptake of primary tumor in NSCLC was presented to 
be correlated significantly with number of viable tumor cells [58], 
characteristics of tumor vitality (such as high tumor cell density, high cell 
proliferation, and extracellular acidosis) [12], and angiogenesis proteins 
(vascular endothelial growth factor: VEGF) [55, 56, 59]. These findings 
indicated that the FDG uptake of primary tumors might reflect the biological 
malignant potential in NSCLC and the relationship between FDG uptake and 
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these biomarkers may lead to a more rational use of FDG-PET scan in NSCLC, 
particularly, in prognosis at diagnosis.  
 
4.4.1. Prognostic value of FDG uptake of primary tumor in stage I and II 
NSCLC 
Stage I and II NSCLC is considered as early stage and can be treated by surgical 
resection as “standard of care” with or without chemotherapy or radiation 
therapy. 
We reviewed 7 studies from Pubmed to focus on prognostic value of FDG 
uptake of primary tumor, measured on PET or PET/CT in patients with stage I-
II NSCLC at diagnosis. All patients were underwent surgical resection after PET 
or PET/CT study. Characteristics of these studies were showed in table 1. 
All these studies used FDG uptake of primary tumor as one of potential 
variables in the survival analysis. FDG on PET or PET/CT was represented by 
maxSUV in 4 studies, by maxSUV and PVC-maxSUV (maxSUV partial volume 
corrected for lesion size) in 2 studies, by both maxSUV and doubling of 
maxSUV in 1 study.  
All these studies showed that FDG uptake of primary tumor was significantly 
correlated with disease free survival or overall survival in early stage NSCLC, 
although the parameters to assess FDG uptake were various. FDG uptake 
represented by maxSUV was identified as independent prognostic indicator in 4 
studies, by maxSUV and PVC-maxSUV in 1 study, by PVC-maxSUV in 1 study 
and by doubling of maxSUV in 1 study. 
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Table 1: Characteristics of the 7 studies focused on the prognostic value of FDG uptake in 
primary tumor for survival in stage I-II NSCLC 
Study Year N of 
patients 
Stage Type of SUV Best 
cut-off 
High FDG uptake 
as prognosis for 
survival 
Goodgame B et al. 
[8] 
2008 136 I maxSUV 5.5 Unfavorable 
Hanin FX et al. 
[9] 
2008 96 I-II maxSUV 7.8 Unfavorable 
Kim HR et al. 
[10] 
2009 107 I maxSUV 4 Unfavorable 
Um SW et al. 
[11] 
 
2009 145 I maxSUV 5.2 and 
13.8* 
Unfavorable 
PVC-maxSUV  Unfavorable 
Dooms C et al.
(a)
 
[12] 
2009 91 I-II maxSUV ≥median Undetermined 
PVC-maxSUV ≥median Unfavorable 
Nair VS et al. 
[13]  
 
2010 75 IA maxSUV 5 Unfavorable 
Agarwal M et al. 
[14] 
2010 363 I-II maxSUV 8.2 Undetermined 
doubling of 
maxSUV 
 Unfavorable 
* 5.2 for Adenocarcinoma and 13.8 for other histology of NSCLC. 
(a)
Prospective study 
 
In a retrospective study to evaluate the prognostic value of the FDG uptake in 
145 patients with resected pathologic stage I NSCLC according to histologic 
types of the tumors, Um SW et al. found that both maxSUV and PVC-maxSUV 
were significantly associated with DFS and there was a difference on the 
optimal cutoff values of maxSUV to predict cancer recurrences according to 
tumor histologies (adenocarcinoma or others) [11]. A prospective study of 
Doom C et al. assessed the FDG uptake, measured as maxSUV in stages I and II 
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NSCLC for its prognostic value and association with in vitro quantitative 
morphology of tumor vitality. The authors showed that PVC-maxSUV ≥ 
median had a prognostic value in completely resected stages I and II NSCLC. A 
high-quantitative FDG uptake was associated with characteristics of tumor 
vitality such as high tumor cell density, high cell proliferation, and extracellular 
acidosis. Meanwhile, SUVmax ≥ median was associated with an increased risk 
of death in univariable analysis, but lost prognostic significance after correcting 
for stage, tumor size and age in multivariable analysis [12]. In a retrospective 
study to determine the prognostic value of maxSUV of the primary tumor in 
curative resection for early-stage (I & II) NSCLC, Agarwal M et al. found that 
maxSUV was not an independent predictor of overall survival.  However, the 
result demonstrated that each doubling of maxSUV as [i.e., each log (base 2) 
unit increase in maxSUV] determined by preoperative PET was associated with 
a 1.28-fold increase in hazard of death in early-stage (I & II) NSCLC.[14, 60] 
Accompany with FDG uptake, the other factors, such as T-classification, age, 
and histology has been identified as the independent predictors for recurrence 
and mortality in NSCLC [8]. The best cut-off of maxSUV to determine 
prognostic significance ranged from 4 to 13.8 in those studies. This may be 
explained by some different characteristics of patients such as tumor-cell type, 
calculation of SUV based on body weight or lean body mass. 
There are some reasons to explain FDG uptake in primary tumor as an 
important prognostic indicator for patients with stage I-II NSCLC. The FDG 
uptake in primary tumor is influenced by multiple biological factors. Glut-1, a 
mediator of glucose uptake and Ki-67, a molecular marker of tumor 
proliferation were commonly overexpressed and correlated with FDG uptake of 
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primary tumor in NSCLC [52-57]. FDG uptake has been also known to be 
related to hexokinase and glucose-6-phosphatase activities in cancer cells [61-
63], tumor blood flow, intratumoral microvessel densities [64], and number of 
viable tumor cells [12, 58]. FDG uptake may reﬂect aggressiveness at the whole 
tumor level. The more aggressive the tumor behavior, the more aggressive the 
biological factors represented by FDG uptake. Therefore, the greater FDG 
uptake in the primary tumor may appear the more aggressive disease and the 
higher risk for recurrence or death in stage I-II NSCLC.  
Thus, FDG uptake should be added to other well-known factors in prognosis of 
stage I-II NSCLC. And it is essential to use FDG uptake as in vivo biomarker 
for stratifying patients at increased risk of recurrence or death for closer 
surveillance or adjuvant chemotherapy after surgery. 
 
4.4.2. Prognostic value of FDG uptake of primary tumor in stage III-IV 
NSCLC 
Stage III and IV NSCLC has been considered as advanced stage. Locally 
advanced NSCLC may be divided into stage IIIA and stage IIIB. Stage IIIA 
NSCLC represents a heterogeneous group (T3 N1, T1–3 N2), from apparently 
resectable tumors with occult nodal microscopic metastasis to unresectable, 
bulky multistation nodal disease [65]. Majority of patients with stage IIIB and 
IV cannot be treated by surgery. Chemotherapy or radio-chemotherapy is 
recommended for these patients. Radiation alone is usually used for symptom 
control. 
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We reviewed 4 studies from Pubmed to focus on prognostic value of FDG 
uptake of primary tumor, measured on PET or PET/CT in patients with stage 
III-IV NSCLC at diagnosis. Characteristics of these studies were showed in 
table 2. 
Three of 4 studies have not identified FDG uptake as prognostic factor for 
survival in patients with stage III and IV NSCLC. Stage of disease, performance 
status, serum albumin levels, bone metastases and metabolic tumor volume 
(MTV) - a volumetric parameter of FDG-PET were better independent 
predictors of survival than maxSUV of the primary tumor in patients with stage 
III and IV NSCLC [16-18]. 
In a study to evaluate the influence of FDG uptake of primary tumor on 
prognosis and occurrence of distant metastases in 159 patients with stage IIIA 
or IIIB NSCLC, Eschmann SM et al found that the incidence of distant 
metastases significantly correlated with meanSUV. Overall survival tended to 
decrease with increasing meanSUV, however, significance was only reached 
when a cut-off of 12.0 was applied (p=0.05). FDG uptake is an independent 
prognostic factor in patients with UICC stage III NSCLC, although less 
distinctively so than has been reported for stage I/II tumors [15].  
It seems that role of FDG uptake of primary tumor in initial prognosis of 
survival was disappointed in advanced NSCLC. FDG uptake of primary tumor 
could not reflect a picture of whole advanced disease, which may be presenting 
potential wide-spread of occult or cleared metastasis. 
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Table 2: Characteristics of the 4 studies focused on the prognostic value of FDG uptake in 
primary tumor for survival in stage III-IV NSCLC. 
Study Year N of 
Patients 
Stage Impression 
Eschmann SM et al. 
[15] 
2006 159 III FDG uptake (meanSUV) was an independent 
prognostic factor in patients with stage III 
NSCLC, although less distinctively so than has 
been reported for stage I/II tumors. 
Overall survival tended to decrease with 
increasing meanSUV. However, significance 
was only reached when a cut-off of 12.0 was 
applied (p=0.05). 
Hoang JK et al.  
[16] 
2008 214 III-IV Stage of NSCLC even in the advanced stage 
was still the best predictor of survival.  
FDG uptake (maxSUV) of the primary tumor 
did not have a signiﬁcant relationship with 
survival and decisions regarding management 
options should not be made based on level of 
metabolic activity of the primary tumor on 
FDG PET for patients with a new diagnosis of 
advanced-stage NSCLC. 
Yan H et al.  
[17] 
 
2011 120 III-IV Metabolic tumor volume (MTV), a volumetric 
parameter of FDG-PET, was an important 
independent prognostic factor for survival and 
a better predictor of survival than maxSUV for 
the primary tumor in patients with advanced 
NSCLC. 
Inal A et al. 
[18] 
2012 120 III-IV FDG uptake (maxSUV) of the primary lesion 
was not associated with prognosis, while 
performance status, serum albumin levels and 
bone metastases were independent prognostic 
factors for overall survival in locally advanced 
or metastatic NSCLC. 
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4.4.3. Prognostic value of FDG uptake of primary tumor in all stage of 
NSCLC 
We extracted 14 studies from Pubmed to focus on prognostic value of FDG 
uptake of primary tumor, measured on PET or PET/CT in patients with stage I 
to III-IV NSCLC at diagnosis. Patients received diversity of therapies due to 
various stages. Eight of 14 studies included all patients underwent surgical 
resection as one of optional treatments after PET study. Twelve studies analyzed 
the influence of maxSUV or meanSUV of primary tumor and other 
conventional parameters on survival. One study used maxSUV and PCV-
maxSUV and one other study used the percentage change in maxSUV 
(maxSUV) between the early and the delayed imaging for survival analysis. 
Characteristics of these studies were showed in table 3. 
Eleven studies identified a high FDG uptake represented by maxSUV or 
meanSUV of the primary tumor as a poor prognostic factor for survival [54, 66-
75]. However, one study demonstrated that maxSUV independently predicted 
overall survival for men but not for women with surgically treated early NSCLC 
[74]. The best threshold of SUV allowing to distinguish between long and short 
survival patients ranged from 5 to 15 regarding to each study. 
Three studies found no signiﬁcant correlation between maxSUV and survival 
[76-78]. Vesselle H et al. reported that neither maxSUV nor PVC-maxSUV 
provided significantly additional prognostic information over stage, tumor size, 
and age [76].  
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Table 3: Characteristics of the 14 studies focused on the prognostic value of FDG uptake in 
primary tumor for survival in all stage I-III/IV NSCLC. 
Study Year 
N of 
Patients 
Stage Type of SUV 
cut-
off 
High FDG uptake 
as prognostic factor 
for survival 
Vansteenkiste et al. 
[66] 
1999 125
(a)
 I-IIIB maxSUV 7 Unfavorable 
Higashi et al.  
[67] 
2002 57
(a)
 I-III meanSUV*  5 Unfavorable 
Jeong et al. 
[68] 
2002 73 I-IV maxSUV 7 Unfavorable 
Downey RJ et al. 
[69] 
2004 100
(a)
 I-IIIB maxSUV 9 Unfavorable 
Sasaki et al. 
[70] 
2005 162 I-III maxSUV 5 Unfavorable 
Borst et al. 
[71] 
2005 51 I-III maxSUV 15 Unfavorable 
Zhang ZJ et al. 
[72]  
2007 82
(a)
 I-III maxSUV 11 Unfavorable 
Nguyen XC et al. 
[54] 
2007 53
(a)
 I-III maxSUV* 7 Unfavorable 
Vesselle H et al. 
[76]  
2007 208
(a)
 I-IV maxSUV* 
PVC-maxSUV* 
7 
7 
Undetermined
 
Undetermined 
Chen X et al. 
[75] 
2008 144 I-IV maxSUV 8 Unfavorable 
Al-Sarraf N et al.  
[73] 
2008 176
(a)
 I-IV maxSUV 15 Unfavorable 
Houseni M et al.  
[77]  
2010 100 I-IV maxSUV 10 Undetermined 
maxSUV 25% Unfavorable 
Wainer Z et al.  
[74] 
2012 189
(a)
 I-IV maxSUV* 8 Unfavorable for 
men. Undetermined 
for women. 
Erdem V et al.  
[78] 
2012 101 I-IV maxSUV 12 Undetermined 
* corrected by lean body mass. 
(a)
 patients underwent surgery treatment after PET study. 
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Houseni M et al. found that dual-phase FDG-PET reﬂected the dynamics of 
glucose metabolism. Percentage of maxSUV change over time, platelet count, 
staging and metastatic status were strong prognostic factors in patients with 
lung adenocarcinoma [77]. 
Patients in these studies were classified in various stages, so it was hard to 
evaluate role of FDG uptake in stratification of early or advanced stages from 
each study. However, these studies found the significant prognosis of 
preoperative FDG uptake in patients with curative intent surgical treatment. 
FDG uptake in primary tumor seemed to be much more related with survival in 
patients in early stage in compare with late stage NSCLC.  
 
4.4.4. Beyond of FDG uptake of primary tumor 
Recent studies were more interested in role of tumor burden measurement on 
survival of patients with NSCLC. Tumor burden measurement includes 
metabolic tumor volume (MTV), number of tumors (TTn) and total lesion 
glycolysis (TLG).  
Whole body MTV and whole body TLG on FDG PET/CT have been used in 
some studies. MTV was deﬁned as the total volume of all tumors in the body in 
milliliters. It provides volumetric information based on FDG-PET/CT and does 
not assess metabolic activity of malignant lesions. TLG provides combination of 
volumetric and metabolic information of FDG PET. Measure of MTV and TLG 
were performed several times and intra- and inter-observer variability of MTV 
and TLG should be assessed. Impression of studies was demonstrated in table 4.  
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Table 4: The impression of the 5 studies to investigate tumor burden measurements on 
survival in NSCLC. 
Study Year N of 
Patients 
Stage Impression 
Lee P et al.  
[19] 
2007 19 I-IV High tumor burden assessed by PET MTV 
(metabolic tumor volume) in whole body was an 
independent poor prognostic feature in lung cancer, 
promising for stratifying patients in randomized 
trials and ultimately for selecting risk-adapted 
therapies.  
Chen HH et al. 
[20]  
2012 105 I-IV Whole body TLG (total lesion glycolysis) was of 
prognostic value for NSCLC. It may be a promising 
tool for stratifying patients with NSCLC for risk-
adapted therapies. 
Liao S et al.  
[21] 
2012 169 I-IV Whole body MTV and whole body TLG on FDG 
PET were prognostic measures independent of 
clinical stage for survival with low inter-observer 
variability and may be used to further stratify 
nonsurgical patients with NSCLC. Pretreatment 
MTV and TLG were better prognostic measures 
than maxSUV and meanSUV of all lesions.  
Liao S et al.  
[24] 
2012 92 IV Whole body MTV and whole body TLG on FDG-
PET were independent prognostic measures for 
survival in patients within Stage IV NSCLC with 
low inter-observer variability.  
Pretreatment MTV and TLG measurements may be 
used to further stratify patients with Stage IV 
NSCLC and was better prognostic measures than 
maxSUV and meanSUV measurements of all 
lesions. 
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Table 4: (continued)  
Study Year N of 
Patients 
Stage Impression 
Zhang H et.  
[22] 
2012 140 I-IV The total number of tumors in whole body and 
number of nodal metastases, as metabolic tumor 
burden measurements in FDG-PET/CT, were 
prognostic markers independent of clinical stage, 
age, gender, and SUV measurement in non-surgical 
patients with NSCLC. 
Zhang H et.  
[23] 
2013 104 I-IV Whole body MTV and TLG on FDG-PET were 
prognostic measures independent of clinical stage 
and other prognostic factors including 
chemoradiation therapy and surgical procedure with 
low inter-observer variability and may be used to 
further risk stratify surgical patients with NSCLC. 
MTV and TLG were better prognostic measures 
than maxSUV and meanSUV.  
 
In a pilot study, Lee P et al. reported that high tumor burden measured by whole 
body metabolic tumor volume (MTV) on FDG-PET/CT was an independent 
poor prognostic feature in lung cancer. An increase in MTV of 25 ml was 
signiﬁcantly associated with increased hazard of 5.4 fold for progression and 
7.6 fold for death [19].  
Studies of Liao S et al. [21, 24] and Zhang H et al. [23] reported that whole 
body MTV and whole body TLG on FDG PET were independent prognostic 
measures for survival. Pretreatment MTV and TLG measurements were better 
prognostic measures than SUVmax and SUVmean measurements and may be 
used to further stratify patients with NSCLC.  
Meanwhile, study of Chen HH et al. [20] found that whole body TLG, whole 
body MTV, lung TLG, lung MTV, maximum SUV, performance status, T stage, 
N stage, clinical stage, and treatment method were significant prognostic factors 
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for PFS in univariate analysis and only whole body TLG and treatment method 
were the two independent prognostic factors for survival in multivariate analysis. 
The 1-year overall survival was 58.8% for patients with whole body TLG >655 
and 84.1% for those with whole body TLG ≤655. While whole-body MTV lost 
it role in prognosis in multivariate analysis [20].  
Another study to determine whether the number of tumors seen in FDG-
PET/CT scans could be a prognostic factor in non-surgical patients with stage I-
IV NSCLC, Zhang H et al. reported that the total number of tumors in whole 
body and number of nodal metastases, as metabolic tumor burden 
measurements in FDG-PET/CT were prognostic markers of overall survival 
independent of clinical stage, age, gender, and SUV of the tumors [22]. 
In this review of the role of FDG-PET and PET/CT in prognosis for patients 
with NSCLC, we recognize that glucose metabolic activity of primary tumor 
based on FDG uptake on FDG-PET and PET/CT should be considered as 
independent prognostic indicator for patients with NSCLC in early stage or 
intent to be treated by surgery as the first choice. FDG uptake of primary tumor 
should be added in the well-known prognostic factors and used to stratify 
patients necessary for further post-operative adjuvant therapy. Tumor burden 
measurement may provide additive prognostic information for patients with 
advanced NSCLC and be evaluated in large prospective cohort studies. 
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5. AIM OF STUDY 
The aim of the prospective study was to test the hypothesis on the additive 
prognostic value of sumaxSUV which is calculated sum of maxSUVs on FDG-
PET/CT of primary tumor, metastatic lymph nodes and metastatic lesions per 
each organ for overall survival in patients with advanced NSCLC. 
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6. MATERIALS AND METHODS 
6.1. Patient population 
We designed the prospective study on patients with advanced stage III-IV 
NSCLC who did not received any specific treatment before undergoing FDG-
PET/CT study at Choray hospital, Vietnam from March 2009 to May 2012. This 
study was approved by the research ethical board of hospital. Eighty three 
patients were enrolled in the study. Patients were indicated to PET/CT study 
from various hospitals in South Vietnam. After PET/CT study and clinical and 
histopathologic diagnoses, the patients were treated following the guideline of 
the referral hospitals. We collected the study data from hospital records and 
clinicians. We contacted the patients or their relatives every 3-6 months to get 
information involving the status of patients. Patients with life expectancy or 
follow-up time of less than 3 months were excluded from the study. 
 
6.2. FDG-PET/CT Imaging 
All patients are fasted for at least 4 hours before FDG-PET/CT study at the 
center of PET/CT and Cyclotron of Choray hospital, Vietnam. The patients with 
diabetes mellitus were recommended to discontinue metformin 2 days prior to 
PET/CT. 
The patients were examined and explained thoroughly on the FDG-PET/CT 
procedure. No one had renal failure and a history of prior allergy-like reaction 
to contrast media. The finger blood glucose level was measured before 
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administration of 
18
F-FDG (FDG). The mean glucose level of all patients was 
102.9±17.0 mg/dl (ranged from 78 to 178 mg/dl).  
The patients were injected the dose of 5.18 MBq/kg (0.14 mCi/kg) of 
18
F-FDG 
which was produced on-site following standard operating procedures. Whole-
body scanning was performed at 60 minutes after 
18
F-FDG injection from skull 
vertex to upper thigh in a PET/CT scanner (Biograph True D w/ true V, Siemens 
Medical System). Firstly, a contrast-enhanced CT scan was performed for the 
attenuation correction and diagnosis, following the guideline of hospital and 
under the supervision of radiologist and nuclear medicine physician. The dose 
of contrast media of Iopromide (Ultravist) or Iopamidol (Iopamiro) 300mg I/ml 
was 1.2 ml/kg body weight of patient and it was infused at a rate of 2 ml per 
second for two-third of volume, then 1 ml per second for the remain one-third 
of volume. The CT scan was started 60 seconds after initiation of intravenous 
contrast material infusion. Then PET scan was acquired in three-dimensional 
(3D) mode with an axial field of view 21.6 cm, slices of thickness of 5 mm and 
an axial and transaxial resolution (FWHM @ 1cm) of 4.7 and 4.2 mm, 
respectively. The PET acquisition time was 3 minutes per bed with slice overlap 
at the borders of the field of view to avoid artifacts. Siemens Multimodality 
workstation with syngo TrueD software were used to display the images of 
attenuation-corrected PET, CT, and fused PET/CT in the transverse, coronal, 
and sagittal planes. A rotating maximum intensity projection image was 
displayed from the software. A nuclear medicine and a radiologist worked 
together in assessment and interpretation of FDG-PET/CT images. 
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6.3. Measurement of FDG uptake on PET/CT 
The measurement and record of FDG uptake on PET/CT were performed by a 
nuclear medicine physician. Volume-of-interest (VOI) was drawn over primary 
tumor and metastatic lesions. Standardized uptake value (SUV) was a semi-
quantitative measure, representative for FDG uptake. SUV was calculated as: 
SUV = radioactivity in VOI (Bq/ml) × body weight (kg) / injected radioactivity 
(Bq). Maximum SUV (maxSUV) was highest SUV representing the maximum 
glucose metabolic activity in tissue. 
Sum of maxSUVs of primary tumor, lymph node and distal metastases per each 
organ in the whole body (sumaxSUV) was defined as sum of the maxSUV of 
primary tumor, the maxSUV of local-regional lymph node metastasis (N1-N3) 
and sum of all maxSUVs of metastatic lesions per each organ in the whole body 
(figure. 1). The data of maxSUVs was updated and sumaxSUV was calculated 
based on Exel software. Distal lymph node was considered as an organ. 
Metastatic lung to other lobes was considered as one more metastatic organ. The 
maxSUV of brain metastasis with or without avid-FDG uptake was all used in 
sumaxSUV. Brain metastatic lesions without avid-FDG uptake detected by 
contrast-enhanced CT or MRI were also measured maxSUV. 
 
  
Primary 
Tumor 
 
Lymph 
node 
 
Distal metastasis 
Organ 1  Organ 2  Organ 3 
           
sumaxSUV = maxSUVpt + maxSUV + maxSUV + maxSUV + maxSUV 
Figure 1: Diagram illustrates how to calculate sumaxSUV 
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(a) 
 
 
(b) 
 
(c) 
 
(d) 
Figure 2: FDG-PET/CT images of NSCLC with lymph node and bone metastases. (a) 
Maximum intensity projection FDG-PET image. (b) maxSUV of lung primary tumor was 
7.7, (c) maxSUV of lymph node was 4.5, and (d) maxSUV of bone metastasis was 11.8 (left 
pubic). SumaxSUV of 24 was calculated on exel software as sum of maxSUVs of lung 
primary tumor, lymph node and bone metastasis. 
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(a) 
 
(b) 
 
 
(c) 
Figure 3: FDG-PET/CT images of NSCLC with left adrenal metastasis. (a) Maximum 
intensity projection FDG-PET image. (b) maxSUV of lung primary tumor was 19.5. (c) 
maxSUV of adrenal metastasis was 17.3. SumaxSUV of 36.8 was calculated on exel 
software as sum of maxSUVs of lung primary tumor and left adrenal metastasis. 
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6.4. Data analysis 
Statistical analysis was performed using SPSS software (version 17.0). 
Overall survival of patient was defined as the time between the PET/CT study 
and death or last follow-up date of patients. 
For analysis of overall survival, sumaxSUV (of primary tumor, lymph node 
metastases and distal metastases per each organ), maxSUV of primary tumor 
(maxSUVpt) and maxSUV of whole body tumors (maxSUVwb) were 
dichotomized into two groups around median values to identify the best 
discriminatory cutoff value for survival prediction. The analysis was conducted 
using the
 
Kaplan–Meyer log-rank test.  
Other prognostic factors, such as, age, gender, tumor-cell type, stage of primary 
tumor, stage of lymph node metastasis, overall stage, size of primary tumor, 
specific treatment were also assessed in survival analysis.  
In addition, sumaxSUV, maxSUVpt, maxSUVwb and size of primary tumor were 
separately entered as continuous values in a Cox proportional hazard model to 
assess their associations with survival.  
Interactions between variables found significant effect on the survival were 
evaluated by multivariate analysis using the Cox proportional
 
hazard model. P 
values of less than 0.05 were considered significant. 
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7. RESULTS 
7.1. Patient characteristics 
A total of 83 patients with NSCLC (49 male and 34 female) were enrolled in the 
present study. Mean age of patients was 58.9 ± 11.0 year old. Mean age was 
58.0 ± 10.1 for male and 60.3 ± 12.2 year old for female patients. The histologic 
subtype was squamous cell carcinoma in 15 patients, adenocarcinoma in 66 
patients, adenosquamous cell carcinoma in 1 patient and large cell carcinoma in 
1 patient. Twelve (24.5%) of 49 male and 3 (8.8%) of 34 female patients had 
squamous cell carcinoma.  
The clinical stage of patients was classified according to stage definition by 
AJCC 6
th
 edition, 2002 [3]. There were 17 patients with stage IIIA, 21 with 
stage IIIB and 45 with stage IV. Among patients with stage IV, there were 23 
patients who had single organ metastasis, 16 patients had 2-organ metastasis 
and 2 patients had either 3, or 4, or 5 organ metastasis. The characteristics of the 
patients are summarized in Table 5. 
There were 28 (33.7%) of 83 patients who had bone metastasis, 16 (19.3%) had 
lung metastasis in other lobes, 12 (14.5%) had renal metastasis, 8 (9.6%) had 
brain metastasis, 6 (7.2%) had liver metastasis, 6 (7.2%) had distal lymph node 
metastasis and 1 (1.2%) had pancreas metastasis 1 (1.2%) had spleen metastasis 
and 1 (1.2%) had soft tissue metastasis. 
After the performance of PET/CT study and a confirmation of diagnosis, 
seventy seven patients received specific treatments and 6 patients had 
supportive treatments.  
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Table 5. Patient characteristics (n=83) 
Characteristics N. of patients % 
Sex   
Male 49 59.0 
Female 34 41.0 
Tumor-cell type   
Squamous cell carcinoma 15 18.1 
Adenocarcinoma  66 79.5 
Adenosquamous cell carcinoma 1 1.2 
Large cell carcinoma 1 1.2 
Tumor stage   
T1 8 9.6 
T2 18 21.7 
T3 17 20.5 
T4 40 48.2 
Lymph node metastasis   
No  9 10.8 
N1 5 6.0 
N2 43 51.8 
N3 26 31.3 
Stage   
Stage IIIA 17 20.5 
Stage IIIB 21 25.3 
Stage IV 45 54.2 
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Among patients with specific treatments, nine patients were treated with surgery, 
chemotherapy and radiotherapy, 10 with surgery and chemotherapy, 18 with 
chemotherapy and radiotherapy or concurrent chemo-radiotherapy, 2 with 
surgery, 35 with chemotherapy and 3 with radiotherapy only. Types of treatment 
was summarized in table 6. 
Table 6. Types of treatment 
Types of treatment N of patients % 
Surgery, chemotherapy, radiotherapy 9 10.8 
Surgery, chemotherapy 10 12.0 
Chemotherapy, radiotherapy 18 21.7 
Surgery 2 2.4 
Chemotherapy 35 42.2 
Radiotherapy 3 3.6 
Supportive treatment 6 7.2 
 
Thirteen (76.5%) of 17 patients with stage IIIA and 8 (12.1%) of 66 patients 
with stage IIIB/IV were treated with surgery. Of 72 patients receiving 
chemotherapy, 66 patients were treated intravenous chemotherapy and 6 
patients were treated orally by erlotinib or gefitinib as the firstline monotherapy. 
The combination of Carboplatin-paclitaxel with or without bevacizumab was 
commonly used for most of the intravenous chemotherapy.  
Median follow-up time was 13.0 months (range, 4-31 months, mean±S.D. = 
14.2±6.8 months). 
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7.2. Univariate analysis of overall survival 
Fifty (60.2%) of the 83 patients were dead during a median follow-up time of 11 
months (range, 4-27 months, mean±s.d. = 12.3±6.2 months). Thirty-three 
patients (39.8%) were alive with a median follow-up time of 15 months (range, 
8-31 months, mean±s.d. = 17.0±6.8 months). 
In the study population of 83 patients, the sumaxSUV ranged between 4 and 
116.4 with median of 26.5 and mean±s.d. of 30.1±19.8. The sumaxSUV was 
continuous variable, so we dichotomized it into 2 groups with 5-unit increase or 
decrease around the median value, relatively. Univariate survival analysis based 
on dichotomizing sumaxSUV revealed that sumaxSUV was significantly 
correlated with overall survival by the log-rank test and a cut-off value of 35 
was identified as the best discriminatory value for overall survival with p = 
0.004. (table 7 and figure 4). 
 
Figure 4. Relationship between various sumaxSUV cut-off values and their discriminative 
significance for overall survival, as assessed by the Log-rank test. 
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Table 7. Relation between cut-off values of sumaxSUV and overall survival as determined by 
the log-rank test. 
Cut-off value 
(sumaxSUV) 
N of 
patients 
Log-rank P  
Cut-off value 
(sumaxSUV) 
N of 
patients 
Log-rank P 
<10 5 0.083  <30 50 0.040 
≥10 78   ≥30 33  
<15 16 0.010  <35 58 0.004 
≥15 67   ≥35 25  
<20 27 0.065  <40 66 0.020 
≥20 56   ≥40 17  
<25 41 0.114  <45 74 0.025 
≥25 42   ≥45 9  
    <50 76 0.066 
    ≥50 7  
 
For maxSUV of primary tumor (maxSUVpt, ranged from 2.8 to 27.6 with 
median of 12.8 and mean±s.d. of 13.5±5.4), and maxSUV of whole body 
tumors (maxSUVwb, ranged from 2.8 to 47.5 with median of 13 and mean±s.d. 
of 14.5±6.6). A dichotomization of maxSUVpt and maxSUVwb was performed 
with 1-unit change around its median value into two groups with cut-off change 
from 7 to 22.  
The analysis did not find any discriminatory cut-off value maxSUVpt and 
maxSUVwb to be significantly correlated with survival. Log-rank p value was 
from 0.139 to 0.962 for maxSUVpt and from 0.168 to 0.851 for maxSUVwb. The 
best discriminatory value for overall survival was 20 for maxSUVpt (p = 0.139), 
and 15 for maxSUVwb (p = 0.168). (table 8 and table 9) 
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Table 8. Relation between cut-off values of maxSUV of primary tumor and overall survival 
as determined by the log-rank test. 
Cut-off value 
(maxSUVpt) 
N of 
patients 
Log-rank P  
Cut-off value 
(maxSUVpt) 
N of 
patients 
Log-rank P 
<7 10 0.962  <15 54 0.749 
≥7 70   ≥15 29  
<8 12 0.792  <16 59 0.664 
≥8 71   ≥16 24  
<9 17 0.775  <17 62 0.398 
≥9 66   ≥17 21  
<10 23 0.389  <18 64 0.317 
≥10 60   ≥18 19  
<11 30 0.538  <19 66 0.372 
≥11 53   ≥19 17  
<12 35 0.691  <20 71 0.139 
≥12 48   ≥20 12  
<13 42 0.907  <21 73 0.418 
≥13 41   ≥21 10  
<14 49 0.466  <22 74 0.563 
≥14 34   ≥22 9  
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Table 9. Relation between cut-off values of maxSUV of whole body tumors and overall 
survival as determined by the log-rank test. 
Cut-off value 
(maxSUVwb) 
N of 
patients 
Log-rank P  
Cut-off value 
(maxSUVwb) 
N of 
patients 
Log-rank P 
<7 7 0.553  <15 48 0.168 
≥7 76   ≥15 35  
<8 9 0.842  <16 55 0.310 
≥8 74   ≥16 28  
<9 13 0.464  <17 32 0.358 
≥9 70   ≥17 18  
<10 20 0.328  <18 59 0.365 
≥10 63   ≥18 24  
<11 26 0.319  <19 62 0.236 
≥11 57   ≥19 21  
<12 32 0.580  <20 68 0.169 
≥12 51   ≥20 15  
<13 40 0.673  <21 70 0.443 
≥13 43   ≥21 13  
<14 46 0.245  <22 72 0.851 
≥14 37   ≥22 11  
 
Suvival analysis was also performed for other potential factors. Overall survival 
was significantly correlated with primary tumor stage (T4 vs. T1-T3), overall 
stage (IV vs. III), gender, and specific treatment. Overall survival was not found 
to significantly relate to age (≤60 vs. >60 years old), size of primary tumor (≤3 
cm vs. >3 cm), tumor-cell type (squamous vs. non-squamous cell carcinoma), 
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lymph node metastasis (N3 vs. N1-N2). The summary of univariate analysis of 
overall survival for all factors was demonstrated in table 10. 
Table 10. Univariate analysis of overall survival. 
Variables Log-rank P 
Gender (male vs. female) 0.029 
Age (>60 vs ≤60 year old) 0.311 
Tumor-cell type (Sqc vs. non-sqc)* 0.053 
Lymph node metastasis (N3 vs. N1-N2) 0.056 
T stage (T4 vs. T1-T3) 0.025 
Stage (IV vs. III) 0.002 
Tumor size (>3 cm vs. ≤3 cm) 0.724 
SumaxSUV (≥35 vs. <35) 0.004 
MaxSUV of primary tumor (> 20 vs. ≤ 20) 0.139 
MaxSUV of whole body tumors (> 15 vs. ≤ 15) 0.168 
Specific treatment (no vs. yes) 0.011 
* Sqc: squamous cell carcinoma, non-sqc: non squamous cell carcinoma. 
 
For the further analysis of continuous variables, maxSUVpt, maxSUVwb, and 
tumor size were not significantly related with overall survival (p = 0.314, 0.112, 
and 0.643, respectively). SumaxSUV was found as the only continuous variable 
associated significantly with overall survival (p = 0.004). A one-unit increase in 
sumaxSUV corresponded to an increase in the hazard ratio for death by a factor 
1.018 (with a 95% confidence interval; 1.006-1.031). 
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7.3. Multivariate analysis with respect to overall survival 
Combinatorial effects and interactions among potential variables correlated with 
overall survival in univariate analysis were examined in Cox proportional 
hazard models. The five variables subjected to this analysis were sumaxSUV, 
primary tumor stage, clinical stage, gender and specific treatment. Multivariate 
Cox analysis identiﬁed T stage (T4 vs.T1-T3), gender (male vs. female), 
specific treatment (no vs. yes) and sumaxSUV ( 35 vs. < 35) remained 
significant independent predictors of overall survival. (table 11) 
Table 11. Results of multivariate analysis of overall survival (Cox proportional hazard model). 
Variable P value Relative risk 95% CI
a
 
T stage (T4 vs.T1-T3) 0.011 2.115 1.185 - 3.775 
Gender (male vs. female) 0.019 2.108 1.131 - 3.930 
Specific treatment (no vs. yes) 0.020 3.215 1.205 - 8.573 
SumaxSUV ( 35 vs. < 35) 0.047 1.921 1.008 - 3.660 
Stage (IV vs. III) 0.056   
a
 95% conﬁdence interval for relative risk. 
Patients with a sumaxSUV of  35 were 1.921 times more likely to die from 
NSCLC than those with a sumaxSUV of ≤35 (p = 0.047). The median survival 
time was 14 months for patients with sumaxSUV 35 and 20 months for those 
with sumaxSUV <35. Relative risk and median survival time of patient groups 
based on T stage, gender and specific treatment were also demonstrated in table 
11 and table 12. 
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Table 12. The median overall survival time based on independent prognostic factors. 
Patient with characteristics: 
Median survival time (month) 
Estimate 
95% Confidence Interval 
Lower Bound Upper Bound 
T Stage   T4 
      T1-T3 
13 
19 
9.8 
15.6 
16.2 
22.5 
Gender   male 
    female 
15 
20 
13.3 
13.0 
16.7 
27 
Specific treatment   no 
    yes 
6 
18 
2.4 
14.7 
9.6 
21.3 
SumaxSUV   35 
   < 35          
14 
20 
9.7 
17.1 
18.3 
23.0 
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Figure 5. Overall survival curves based on T stage.  
The patients with T4 stage (n=40) had median survival time of 13 months, that was lower 
than those with T1-T3 stage (n=43, 19 months). 
 
 
Figure 6. Overall survival curves based on gender.  
Male patients (n=49) had median survival time of 15 months, that was lower than female 
patients (n=34, 20 months). 
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Figure 7. Overall survival curves based on treatment.  
The median survival time was 18 months for patients with specific treatment (n=77), 
compared to only 6 months for those without specific treatment (n=6). 
 
 
 
Figure 8. Overall survival curves based on sumaxSUV cut-off.  
The patients with sumaxSUV 35 (n=25) had median survival time of 14 months, that was 
lower than those with sumaxSUV <35 (n=58, 20 months). 
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7.4. Survival analysis in patients with stage IV NSCLC 
In 45 patients with metastatic NSCLC, thirty four patients (75.6%) were dead 
during follow-up at a median 11 months (range, 4-26 months, mean±s.d. = 
11.8±5.9 months) and 11 patients (24.4%) were alive with a median follow-up 
time of 14 months (range, 8-28 months, mean±s.d. = 15.7±6.1 months).  
A univariate analysis demonstrated sumaxSUV with cut-off of 35 and specific 
treatment were correlated with overall survival with a log-rank p value of 0.33 
and 0.23, respectively. No significant correlation was found between overall 
survival and one of other factors, such as gender, T stage, N stage, maxSUVpt, 
maxSUVwb, size of primary tumor, tumor-cell type, age, and number of 
metastatic organs in univariate analysis. 
SumaxSUV and specific treatment both remained significant on multivariate 
analysis in Cox Proportional Hazard Model with p value of 0.021 for 
sumaxSUV and 0.013 for specific treatment. Patients with metastatic NSCLC 
who had a sumaxSUV of  35 were 2.371 times more likely to die from disease 
than those with a sumaxSUV of ≤35. The median survival time was 11 months 
for patients with sumaxSUV 35 compared to 19 months for those with 
sumaxSUV <35. 
Patients with metastatic NSCLC who did not received any specific treatment, 
were 3.568 times more likely to die. The median survival time was 6 months for 
patients without specific treatment compared to 15 months for those with 
specific treatment.  
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8. DISCUSSION 
The main findings of this study is that sum of maximum glucose metabolism of 
primary tumor, local-regional lymph node metastasis and distal metastasis per 
each organ in the whole body determined by sumaxSUV measurement and other 
factors such as gender, tumor stage and specific treatment are the independent 
prognostic factors for overall survival. SumaxSUV was presented more 
significant in survival prognosis for subgroup of metastatic NSCLC. The 
maxSUV of primary tumor and maxSUV of whole body tumors did not provide 
prognostic information in patients with advanced NSCLC.  
A sumaxSUV cut-off of 35 was the best discriminative value for overall survival. 
Moreover, sumaxSUV was also a continuous variable which showed significant 
correlation with overall survival in present study.  
The maximum glucose metabolism of primary tumor represented by maxSUV 
of FDG uptake on PET or PET/CT has been reported as initial prognostic factor 
for early stage NSCLC in some previous studies [8-14]. In the early stage 
NSCLC, the disease is localized and able to be treated by curative intent 
surgery. The risk of disease recurrence after surgery may be partially 
determined by the aggressive biologic behavior of primary NSCLC. High FDG 
uptake of primary tumor reflects the variety of aggressively biological processes 
in the whole tumor which can consist of the glucose metabolic activity 
represented by Glut-1 over expression [52-55], proliferative activity by Ki-67 
expression [54-57], hexokinase and glucose-6-phosphatase activities [61-63], 
number of viable tumor cells [12, 58], angiogenesis [55, 56, 59], tumor blood 
flow, and intratumoral microvessel densities [64]. Thus, high FDG uptake of 
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primary tumor, presented by maxSUV on PET or PET/CT was significantly 
associated with poor prognosis of early stage NSCLC [8-14]. 
The present study did not identified maxSUV of primary tumor (maxSUVpt) and  
maxSUV of whole body tumors (maxSUVwb) as predictors of survival in 
advanced NSCLC. This findings are consistent with some previous studies, 
which reported that maxSUVpt [16-18], and maxSUVwb [20, 21, 23, 24] were 
not signiﬁcantly associated with survival. Treatment options should not be made 
based on level of metabolic activity of the primary tumor as well as the 
metastatic lesion only in advanced NSCLC.  
In advanced NSCLC, the aggressive behavior of the primary tumor only may 
not reflect the whole disease status when the high risk of occult widespread 
dissemination of the tumor cells or actually metastasis to other organs through 
lymphatic or blood vessels. Moreover, the aggression of lesions in different 
organs commonly presents various glucose metabolic activities and maxSUVwb 
reflects the aggression of only one in variety of impaired organs of disease. Risk 
of death can be original from organ’s malignant lesions with maxSUV that can 
be less than maxSUVwb. Thus, glucose metabolism of the primary tumor or 
metastatic lesions of single organ only could be not enough to provide additive 
prognostic information in advanced NSCLC. 
In the present study, sumaxSUV was identiﬁed as an important predictor for 
advanced NSCLC, independent of tumor stage, gender and specific treatment 
after analyzing for combinatorial effects and interactions. The sumaxSUV 
measure has been not investigated so far. The sumaxSUV, presenting all 
maximum glucose metabolic activities from primary tumor, loco-regional 
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lymph nodes and metastatic lesions per each organ may reflect the aggressive 
levels of all organs with active malignant lesions in the whole body with 
regarding to aspect of metabolic activity. 
FDG uptake in primary tumor significantly correlated with the incidence of 
regional lymph node metastasis [25, 26], and distant metastases in NSCLC [15, 
27]. However, FDG uptake in primary tumor has not been reported to be 
correlated with the aggression of metastatic organs. While the risk of death in 
patients with advanced NSCLC can come from metastatic lesions in various 
organs. This study showed that the sumaxSUV seemed to be suitable parameter 
presenting biologic behavior and aggressiveness of whole body disease. Thus, it 
should be considered to add sumaxSUV into known prognostic factors in 
advanced NSCLC. 
Recently, the impact of metabolic tumor burden on survival prognosis for 
patients with NSCLC has been assessed in several studies [19-24]. High tumor 
burden measured by whole body metabolic tumor volume (MTV) and whole 
body total lesion glycolysis (TLG) on FDG-PET/CT has been reported as 
independent poor prognostic feature in NSCLC [19-21, 23, 24]. MTV provides 
volumetric information based on FDG-PET/CT and does not assess metabolic 
activity of malignant lesions. TLG provides metabolic and volumetric 
information based on FDG-PET/CT derived from the whole body. MTV and 
TLG have been recommended to be used to stratify patients with NSCLC [19-
21, 23, 24]. However, those studies did not include patients with brain 
metastasis, because whole body PET/CT did not cover the whole brain and the 
measurement of MTV and TLG gave a result of low inter-observer variability.  
 51 
Another measure of metabolic tumor burden on FDG-PET/CT is to count the 
total number of tumors in whole body (TTn) and number of nodal metastases 
(Nn). TTn and Nn have been found to be prognostic markers of overall survival, 
independent of clinical stage, age, gender, and SUV of the tumors in non-
surgical patients with stage I-IV NSCLC [22].  
This present study demonstrated a new measurement of metabolic tumor burden, 
so-called sumaxSUV, which has proved prognostic value in advanced NSCLC, 
particularly in metastatic stage. Lesions with highest FDG uptake per each 
organ are easily selected in FDG-PET/CT and the calculation of sumaxSUV is 
simple and reproducible.  
Another principal finding of this study is that T4 stage was significantly 
associated with poor prognosis. Overall stage (IV vs. III) was only correlated 
with survival in univariate analysis (p = 0.002) and lost significant statistically in 
multivariate analysis (p = 0.056). This can be explained that clinical stages of 
patients were classified based on staging system of AJCC 6
th
 edition. Malignant 
pleural effusion belongs to T4 stage following AJCC 6
th
 edition, instead of M1a 
stage by AJCC 7
th
 edition [79]. Eight (38.1%) of 21 patients with stage IIIB and 
14 (31.1%) of 45 patients with stage IV had malignant pleural effusion or 
epicardial invasion (1 case) in this study.  
There was a significant difference in survival between male and female patients. 
Male had shorter survival time than female patients did. No significant 
difference in age and tumor-cell type was seen between male and female 
patients (p>0.05, not presented in result) and smoking status was not surveyed 
from this study. While some previous studies showed that women with lung 
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cancer have better survival than men with lung cancer. It was likely that women 
were smoked less intensively, disease-diagnosed at an earlier age and had 
histology of adenocarcinoma [80-82].  
This study had certain limitations. Patients were enrolled with different stages 
IIIA to IV NSCLC and received various treatments. Thirteen of 17 patients 
(76.5%) with stage IIIA and 8 of 66 patients (12.1%) with stage IIIB/IV were 
treated with surgery. We analyzed survival involving only one factor of specific 
treatment which represented for surgery, chemotherapy and radiation or 
combination treatment. The impact of each therapeutic method on result of 
survival was not analyzed.  
One of important factors for survival prognosis is performance status of patients 
which not assessed in this study. However, we found that most of patients in 
poor performance status could not suffer a specific therapy and had shorter 
survival time.   
A contrast media used during the FDG PET/CT helped attenuation correction of 
PET images, better localization and anatomic diagnosis. Contrast-enhanced CT 
can influence on measurement of SUV. MaxSUV has been demonstrated to be 
increased in the contrast-enhanced PET/CT at all anatomic sites. The mean 
differences of maxSUV between enhanced and non-enhanced PET/CT were 
5.9±3.9% for lung lesions, 6.3±3.8% for lymph nodes and 3.6%±3.4% for 
metastatic lesions, respectively [83]. Contrast-enhanced CT is suitable for 
attenuation correction in combined PET/CT and did not produce any clinically 
significant artifact in patients with lung cancer [83, 84].  
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9. CONCLUSION 
Sum of the maxSUVs of primary tumor, loco-regional lymph node and distal 
metastases per each organ on FDG-PET/CT is prognostic measure, independent 
of tumor stage, gender and specific treatment in advanced NSCLC. SumaxSUV 
may be better than maxSUVpt and maxSUVwb in prediction of survival in 
advanced NSCLC. A large prospective cohort study is necessary to validate 
these results. 
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11. APPENDIX 
 
LIST OF PATIENTS ENROLLED IN THE STUDY 
 
Pts Age M/F H 
Staging Specific treatment 
Status 
Duration  
(months) T N M TNM S C R 
1 67 F A 4 3 1 4 N N N D 8 
2 55 M S 2 3 1 4 N N Y D 16 
3 51 F A 4 3 1 4 N Y N D 18 
4 67 F A 4 3 0 3B N Y N D 6 
5 53 M A 4 2 1 4 N Y Y D 13 
6 51 M A 4 3 1 4 N Y Y D 26 
7 82 M A 1 1 1 4 N N N D 19 
8 68 F S 4 3 1 4 N Y Y D 11 
9 42 M A 2 2 1 4 N Y N D 21 
10 42 M A 4 3 1 4 N Y N D 15 
11 39 M S 4 3 0 3B N Y N D 13 
12 68 F A 4 2 1 4 N Y N D 6 
13 60 F S 2 2 0 3A N Y N D 11 
14 52 M S 1 2 0 3A Y Y N D 27 
15 56 F A 1 2 1 4 N Y N A 23 
16 33 F A 1 0 1 4 N Y Y D 14 
17 60 M A 2 3 1 4 N Y N D 18 
18 53 F A 1 2 0 3A Y Y Y A 31 
19 72 F A 1 2 1 4 N N N D 6 
20 73 M A 4 2 0 3B N Y Y D 4 
21 42 M A 4 3 1 4 N Y N D 7 
22 55 F A 4 2 1 4 N Y Y D 20 
23 52 F A 2 2 0 3A Y Y N D 27 
24 65 M L 2 2 0 3A Y N N D 14 
25 70 M AS 4 3 0 3B N Y N A 29 
26 61 M A 3 2 1 4 Y Y N D 9 
27 52 F A 3 2 1 4 N Y Y A 15 
28 50 M S 1 2 0 3A Y Y N A 29 
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29 60 F A 3 3 0 3B N Y Y A 29 
30 58 F A 4 2 1 4 N Y N A 28 
31 82 F A 4 1 1 4 N Y N D 5 
32 76 F A 2 3 0 3B N Y Y D 22 
33 64 M A 4 0 1 4 N Y N D 15 
34 63 M A 1 2 1 4 N Y N D 19 
35 52 M A 2 0 1 4 N Y Y D 10 
36 63 M A 2 2 0 3A Y Y Y D 9 
37 54 M A 2 2 0 3A Y Y N A 23 
38 81 M A 3 2 1 4 N Y N A 11 
39 46 M A 3 0 1 4 N Y N D 15 
40 55 M S 2 2 1 4 N Y N D 6 
41 56 M S 3 3 1 4 N Y N D 5 
42 67 F A 4 2 0 3B N Y N A 22 
43 54 F A 4 2 1 4 N Y Y D 12 
44 55 F A 4 3 0 3B Y Y N D 18 
45 84 F A 2 2 1 4 N Y N A 22 
46 61 M A 2 2 0 3A N Y Y A 21 
47 58 M A 2 2 0 3A Y Y Y A 21 
48 74 M S 4 2 0 3B N N Y D 10 
49 54 M A 2 0 1 4 N Y N D 9 
50 40 M A 4 0 0 3B N Y N A 20 
51 74 M A 4 2 1 4 Y Y N D 5 
52 56 M A 3 2 1 4 N Y Y D 20 
53 59 M S 2 2 0 3A Y Y Y D 14 
54 51 M S 4 3 1 4 N N N D 5 
55 66 M S 4 2 0 3B Y Y N D 15 
56 47 M A 4 3 1 4 N Y N D 9 
57 48 F A 4 2 0 3B N Y N A 17 
58 58 M A 2 2 0 3A Y Y N A 16 
59 71 M S 2 3 1 4 N Y N D 14 
60 49 M S 4 2 0 3B Y Y Y D 8 
61 51 F A 4 3 1 4 N Y N D 11 
62 53 F A 3 2 0 3A Y Y Y A 17 
63 61 M A 4 3 1 4 N Y N D 6 
64 47 M A 4 2 1 4 N Y N D 6 
65 56 M A 3 3 0 3B N Y N A 15 
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66 49 F A 4 0 1 4 N Y Y A 16 
67 58 M A 4 1 0 3B Y Y Y D 5 
68 58 M A 4 2 0 3B Y Y N A 14 
69 79 F S 3 2 1 4 N Y N A 14 
70 40 F A 4 3 1 4 N Y N A 13 
71 60 M A 3 3 0 3B N Y Y D 10 
72 44 F A 4 0 0 3B N N N A 12 
73 66 F A 4 2 0 3B N Y Y A 12 
74 67 F A 3 3 0 3B N Y Y A 9 
75 60 F A 4 2 1 4 N Y N A 12 
76 56 F A 4 2 0 3B Y Y Y A 12 
77 70 M A 3 0 1 4 N Y N A 11 
78 61 M A 3 2 0 3A N Y Y A 11 
79 83 F A 3 1 0 3A Y N N A 10 
80 63 F A 3 1 0 3A N N Y A 9 
81 66 M A 3 2 0 3A Y Y Y A 10 
82 56 M A 4 3 1 4 N Y N A 8 
83 58 M A 4 3 1 4 N N N D 4 
Abbreviations: 
Pts: patients, M/F: Male/Female. 
H: Histology (A: Adenocarcinoma, S: Squamous cell carcinoma, AS: Adenosquamous cell carcinoma and L: 
Large cell carcinoma) 
T: Tumor, N: Lymph node, M: Metastasis, TNM: Tumor - Node - Metastasis. 
Specific treatment (S: Surgery, C: Chemotherapy, R: Radiation, Y: yes, N: no) 
Status ( A: Alive and D: deceased) 
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LIST OF PATIENTS ENROLLED IN THE STUDY (continued) 
 
Pts 
T 
size 
maxSUV Sumax- 
SUV T LN Lu Bo Li Br Ad Sp Pa So d-LN 
1 2.6 11.7 10.8 2.4 9 
       
33.9 
2 9.5 22.1 13.4 14.5 
        
50 
3 7 23.2 2.7 15 
        
40.9 
4 3 14.2 2.3 
         
16.5 
5 6.2 12.4 6.7 5.8 
        
24.9 
6 7.2 11.6 4.6 
 
6.1 7.3 
      
29.6 
7 2.4 17.8 6.2 
 
7.2 
       
31.2 
8 5.7 20.3 34.6 
 
20.8 14.1 10.1 11 
    
110.9 
9 3.7 7.7 4.5 
 
11.8 
       
24 
10 4.6 13 8 1 12.3 
  
4.6 
    
38.9 
11 6 21.7 14.1 
         
35.8 
12 3 6.7 7.1 
 
3 
  
2.8 
    
19.6 
13 7.4 15 7.1 
         
22.1 
14 3 13.6 9.8 
         
23.4 
15 2 11.9 8 
 
23.9 
       
43.8 
16 2.5 13.2 
    
16.6 
     
29.8 
17 3.5 19.4 8.9 
 
11.8 
  
6 
    
46.1 
18 2.3 2.8 2.4 
         
5.2 
19 2.5 8.5 8.3 
 
15.2 
  
11.4 
    
43.4 
20 5.2 12.1 9.5 
         
21.6 
21 2.7 7.9 4.5 
 
9.2 
       
21.6 
22 5.8 9.9 3 
 
2.1 
  
9.8 
    
24.8 
23 4.5 22.4 4.4 
         
26.8 
24 5.3 11.3 2.2 
         
13.5 
25 5.8 15.8 11.7 
         
27.5 
26 7.5 24.3 2.8 
    
16.2 
    
43.3 
27 2.4 19.2 4 
   
8.9 
     
32.1 
28 2.2 10.9 3.7 
         
14.6 
29 9.4 19.6 15.2 
         
34.8 
30 2.8 13 2.8 0.5 7.4 
       
23.7 
31 2 6 4.9 
 
5.1 5.3 
     
5.2 26.5 
 63 
32 4.5 6.7 2.9 
         
9.6 
33 2.3 14.6 
  
23.3 
       
37.9 
34 2.5 6.6 6.3 0.9 
        
13.8 
35 7 6.3 
 
3.7 
  
6.6 
     
16.6 
36 3.2 10.3 6.2 
         
16.5 
37 3.7 14.4 6.7 
         
21.1 
38 4.2 22.8 11.2 
 
17.8 9.5 
 
9.1 
  
27.2 
 
97.6 
39 5.6 24 
    
17.1 
     
41.1 
40 7 27.6 21.9 
 
47.5 
  
19.4 
    
116.4 
41 4 10.9 14.6 8 2.1 
      
21.5 57.1 
42 3.8 12.1 8.3 
         
20.4 
43 5.2 16 5.1 
 
6.8 
       
27.9 
44 4.5 9.2 5.4 
         
14.6 
45 5 13 10.9 10.6 
        
34.5 
46 3.9 8.9 7.7 
         
16.6 
47 6.4 16.7 18.5 
         
35.2 
48 5.2 18.7 5.8 
         
24.5 
49 3.2 19.5 
  
3.2 
  
14.1 
    
36.8 
50 3.2 4 
          
4 
51 6.7 15.2 10.5 
        
4.9 30.6 
52 4.8 15.5 11.2 3.1 
        
29.8 
53 5.5 22.1 13.7 
         
35.8 
54 7 14.5 19.5 8.8 
  
5.8 
     
48.6 
55 4 19.7 12.4 
         
32.1 
56 9 12.1 9.1 
 
3.4 8.5 13.1 9 
   
8.4 63.6 
57 3.1 16.3 3.5 
         
19.8 
58 4.2 9 2.5 
         
11.5 
59 3.8 14.7 12.2 
 
12.4 
       
39.3 
60 4 13.6 8.7 
         
22.3 
61 2.3 12.8 10.4 
 
9 
      
8.3 40.5 
62 5.6 22.2 19 
         
41.2 
63 3.8 11.4 13 5.1 
     
10.2 
  
39.7 
64 4.3 4.9 7.5 2.2 5.8 
       
20.4 
65 3.7 9.4 3.3 
         
12.7 
66 3.5 10.9 
    
8.2 
     
19.1 
67 5.8 10.9 7.9 
         
18.8 
68 4.5 6.5 4.3 
         
10.8 
 64 
69 5 12.5 5.7 
 
11.5 
       
29.7 
70 4.7 17.2 12.4 4.1 
        
33.7 
71 7 10.7 5.2 
         
15.9 
72 2 8.9 
          
8.9 
73 7.5 8.5 3.5 
         
12 
74 4.2 15.9 11.4 
         
27.3 
75 5 13 10.4 
 
12 6.5 
 
5 5.7 
  
5.7 58.3 
76 8.7 8.3 5.5 
         
13.8 
77 7.5 10.7 
  
8.9 
       
19.6 
78 14.3 9.5 3.4 
         
12.9 
79 7 9.55 3.7 
         
13.25 
80 2.8 12.4 5.3 
         
17.7 
81 6.4 18.3 6.4 
         
24.7 
82 9 4.5 2.6 2.8 
        
9.9 
83 4.5 20.1 15.1 
 
7.1 
       
42.3 
Abbreviations: 
T: tumor, LN: lymph node, Lu: lung, Bo: bone, Li: liver, Ad: adrenal, Sp: spleen, Pa: pancreas, So: soft tissue,  
d-LN: distal lymph node metastasis. 
 
 
 
 
 
 
 
